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454HLA-Mismatched Unrelated Donors as an Alternative
Graft Source for Allogeneic Stem Cell Transplantation
after Antithymocyte Globulin-Containing
Conditioning Regimen
Nicolaus Kro¨ger,1 Tatjana Zabelina,1 Thomas Binder,2 Francis Ayuk,1 Ulrike Bacher,1
Gitta Amtsfeld,1 Heinrich Lellek,1 Johanna Schrum,1 Rolf Erttmann,1
Thomas Eiermann,2 Axel Zander1Between August 1996 and December 2004, 369 patients with a median age of 41 years (range: 1-68 years)
received stem cell transplantation (SCT) from unrelated donors after an antithymocyte-globulin (ATG)-
containing conditioning regimen. In 268 patients, complete molecular typing (4-digit) of HLA-A, -B, -C,
-DRB1, and -DQB1 was available: 110 patients were completely matched for 10 alleles, 91 patients had 1
allele-mismatch (9/10), and 67 patients were mismatched for 2-4 alleles (6-8/10). The incidence of grade
II-IV acute graft-versus-host disease (aGVHD) was 33% in the 10/10, 41% in the 9/10, and 40% in the
6-8/10 group, respectively (P 5 .1). The cumulative incidence of treatment-related mortality (TRM) and
relapse among the groups were similar (27%, 31%, and 32%, P 5 .2; and 28%, 27%, and 26%, P 5 .9. After
a median follow-up of 35 months (range: 3-120 months), the estimated 5-year disease-free survival (DFS)
was 42% and did not differ among the 10/10, the 9/10, and the 6-8/10-mismatched groups (45% versus
42% versus 39%) (P 5 .5). In multivariate analysis, only age (hazard ratio [HR] 1.013) (P 5 .004) and bad-
risk disease (HR 1.975) (P\ .001) were independent risk factors for DFS. In conclusion, pretransplant
ATG allows allogeneic SCT from unrelated donors with HLA disparities.
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Hematopoietic stem cell transplantation (SCT)
fromHLA-identical siblings or adult unrelated donors
can cure several malignant and nonmalignant hemato-
logic diseases and has become an established treatment.
For patients lacking an HLA-identical sibling, more
than 10 million unrelated volunteers worldwide are
available for donation of hematopoietic stem cells.
Despite this increasing number of unrelated donors,
up to 30% of the patients will not find a completely1Department of Stem Cell Transplantation, University
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patientswithhematologicmalignancieswho lack a suit-
able matched related or unrelated donor, encouraging
results have been obtained after transplantation of
hematopoietic stem cells from an HLA-haploidentical
related donor [1,2], or after transplantation of 1 or 2
umbilical cord blood units either after myeloablative
[3,4] or after reduced intensity conditioning (RIC)
[5,6]. Both HLA-haploidentical related and umbilical
cord blood grafts can be obtained rapidly for the
majority of patients. For unrelated SCT, increasing
genetic disparity, particularly for the human leukocyte
antigen (HLA) molecular system is associated with an
increased risk of acute and chronic graft-versus-host
disease (aGVHD, cGVHD) and a higher nonrelapse
mortality (NRM), resulting in a lower survival after he-
matopoietic SCT [4,7-22]. Therefore, for patients
without a completely HLA-matched donor, there are
still questions such as how the best mismatched donor
can be selected, which mismatch can be tolerated, and
which GVHD prophylaxis is most appropriate. An
analysis of the National Marrow Donor Program
(NMDP) recently showed that allele level-matching
Biol Blood Marrow Transplant 15:454-462, 2009 455HLA-Mismatched Donor as an Alternative Stem Cell Sourcefor HLA-A, -B, -C, and -DRB1 is preferred in the
selection of adult unrelated donors, and if mismatching
is unavoidable, mismatches at HLA-B or -C may be
better tolerated than those in -A or -DRB1 [7]. How-
ever, in this study each single mismatch was associated
with a 10% decrease in survival [7]. Therefore, trans-
plant-related strategies such as improved graft-versus-
host prophylaxis, should be investigated to determine
the influence of allele- and antigen-mismatched trans-
plantation from unrelated donors. Smaller studies sug-
gest that antithymocyte globulin (ATG) can overcome
the negative effect of mismatched unrelated SCT [23-
29]. In the current study, we investigated the impact
of using pretransplantation ATG (ATG Fresenius)
as part of the conditioning regimen on outcome of
allele- and antigen-mismatched SCT from unrelated
donors.
PATIENTS AND METHODS
Patients
Between August 1996 and December 2004, 369
patients received stem cell grafts from unrelated do-
nors at the Department of Stem Cell Transplantation
of the University Hospital Hamburg-Eppendorf. In
268 cases, complete molecular typing (4-digit) of
HLA-A, -B, -C, -DRB1, and -DQB1 was available
for donor as well as for recipients. The median age
of patients was 41 years (range: 1–68 years). Diagnoses
were acute leukemia or myelodysplastic syndromes
(MDS) in 135 patients, chronic myeloproliferative
disease (chronic myelogenous leukemia [CML] or
primary myelofibrosis [PMF]) (n 5 53), lymphoid
malignancy (chronic lumphocytic leukemia [CLL],
non-Hodgkin leukemia [NHL], Hodgkin disease
[HD], multiple myeloma [MM]) (n5 60), or other dis-
eases, such as aplastic anemia (AA) and nonmalignant
diseases (n 5 20). Stem cell source was either bone
marrow (n 5 103) or peripheral blood stem cells
(PBSC; n 5 165). The patients were classified either
as ‘‘good risk’’ (n 5 108; CML in first chronic phase,
acute leukemia in first remission,MDS-refractory ane-
mia [MDS-RA] or MDS-refractory anemia with ring
sideroblasts [MDS-RARS], or myelofibrosis and non-
malignant diseases) or as ‘‘bad risk’’ (n 5 160; acute
leukemia not in remission or more than first remission,
MDS-refractory anemia with excess blasts [MDS-
RAEB] or -RAEB-t, CML in accelerated phase or blas-
tic phase, refractory NHL, and MM). The majority of
the patients (n5 163) received standard myeloablative
conditioning, whereas 105 patients received a dose-
conditioning regimen (for details, see Table 1). The
matched and the mismatched group did not differ
significantly in age, sex, risk category, graft source,
cytomegalovirus (CMV)-status, conditioning, or
CD341 transplanted cells. The 6-8/10-mismatched
group, however, received a significantly higher doseof ATG (ATG Fresenius, Gra¨felfing, Germany) (90
mg/kg body weight [BW] versus 60 mg/kg BW).
According to high-resolution HLA typing, 110 of the
patients were completely matched for 10 alleles,
whereas 91 patients had at least 1 allele-mismatch (9/
10), and 67 patients were mismatched for 2-4 alleles
(6–8/10). Of these 67 patients, 44 had 2 mismatches,
15 had 3 mismatches, and 8 patients had 4 mismatches.
The majority of the patients had mismatches in C-
locus. The detailed mismatches in class I and II are
listed in Table 2.
HLA Typing
HLA-A, -B, -C, -DRB1, and -DQB1 alleles were
typed with sequence-specific oligonucleotide probes.
Genomic DNA of patients and donors was isolated
from 5 mL of blood using the QIAamp DNA Maxi
Blood Kit (Qiagen, Chatsworth, CA). The remaining
ambiguities in alleles with population frequencies
.1/1000 were resolved by sequence-based typing
and/or sequence specific amplication.
GVHD Prophylaxis
All patients received ciclosporine A (CsA) starting
on day –1 at 3 mg/kg i.v. infusion and later switched to
an equivalent oral dose as soon as possible. CsA was ta-
pered off as from day1140 and discontinued between
days 1180 and 1200, if no GVHD occurred. Metho-
trexate (MTX; 10 mg/m2) was administered on days
11, 13 and 16. aGVHD and cGVHD were graded
according to international standard [30,31].
Supportive Care
All patients were nursed in reverse isolation in con-
ventional or laminar air flow room. Acyclovir and
fluconazol or itraconazol were routinely administed
to all patients. Prophylaxis against Pneumocystis carinii
consisted of cotrimoxazole or pentamidine inhalation.
All blood products were irradiated with 25 Gy. CMV-
negative patients received only CMV-negative blood
products. CMV-positive patients were monitored at
least weekly for CMV infection by polymerase chain
reaction (PCR) and/or antigenemia assay. Neutro-
penic fever was treated with broad-spectrum antibi-
otics according to the centers’ policy.
Statistical Analysis
Endpoints were overall survival (OS), disease-free
survival (DFS), nonrelapse mortality (NRM), inci-
dence of relapse, incidence and severity of aGVHD
and cGVHD. Characteristics of patients were ex-
pressed as median and range for continous variables
and frequencies for categoric variables. Categoric
data were compared by chi-square test and Fisher’s
exact test. Actuarial curves were estimated according
the Kaplan-Meier method and the significance was
Table 1. Patients’ Characteristics
Number of Patients All Patients n 5 268
Matched 10/10
(n 5 110)
Mismatched 9/10
(n 5 91)
Mismatched 6-8/10
(n 5 67) P-Value
Age (years) (median) 41 (range, 1-68) 41 (range, 1-67) 41 (range, 1-65) 35 (range, 1-68) .2
Patients’ sex
Male n 5 163 n 5 68 n 5 54 n 5 41 .9
Female n 5 105 n 5 42 n 5 34 n 5 26
Diagnosis
ALL, AML, MDS n 5 135 n 5 55 n 5 44 n 5 36 .09
CML, PMF n 5 53 n 5 20 n 5 25 n 5 8
CLL, NHL, HD, MM n 5 60 n 5 29 n 5 17 n 5 14
Others n 5 20 n 5 6 n 5 5 n 5 9
Risk category
Bad n 5 160 n 5 68 n 5 52 n 5 40 .8
Good n 5108 n 5 42 n 5 39 n 5 27
Donors’ sex
Male n 5 183 n 5 78 n 5 61 n 5 43 .8
Female n 5 83 n 5 32 n 5 29 n 5 22
Graft source
Bone marrow n 5 103 n 5 35 n 5 37 n 5 31 .1
Peripheral blood
stem cells
n 5 165 n 5 75 n 5 54 n 5 36
AB0-compatibility
Identical n 5 107 n 5 46 n 5 42 n 5 19 .04
Major n 5 97 n 5 38 n 5 25 n 5 34
Minor n 5 55 n 5 24 n 5 20 n 5 11
CMV-serostatus (patients)
Positive n 5 147 n 5 58 n 5 45 n 5 44 .1
Negative n 5 121 n 5 52 n 5 46 n 5 23
Conditioning
Standard n 5 163 n 5 62 n 5 57 n 5 44 .4
Reduced intensity n 5 105 n 548 n 5 34 n 5 23
Busulfan-based
Yes n 5 136 n 5 54 n 5 51 n 5 31 .4
No n 5 132 n 5 56 n 5 40 n 5 36
TBI-based
Yes n 5 62 n 5 24 n 5 20 n 5 18 .7
No n 5 206 n 5 86 n 5 71 n 5 49
ATG-dose (median) 60 (range, 20-120) 60 (range, 20-120) 60 (range, 20-90) 90 (range, 30-90) .001
CD34+ transplanted cells/kg BW (106) 6 (range, 0.35-31) 6.0 (range, 1-31) 7.0 (range, 0.35-27.0) 6.0 (range, 1-19) .7
Median follow-up (months) 38 (range, 4-119) 39 (range, 4-104) 39 (range, 5-119) 32 (range, 4-97) .9
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leukemia; CLL, chronic lymphoblastic leukemia; CML, chronic myelogenous leu-
kemia; CMV, cytomegalovirus; TBI, total body irradiation; ATG, antithymocyte globulin; BW, body weight; MM, multiple myeloma; HD, Hodgkin disease;
NHL, non-Hodgkin lymphoma; MDS, myelodysplastic syndromes; PMF, primary myelofibrosis.
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transplantation to death from any cause. Patients who
were still alive at follow-up were censored at the last
follow-up date. DFS was calculated from transplanta-
tion until relapse/progression or death from any cause.
Patients who were still alive at time of analysis were
censored at last follow-up date. Treatment-related
mortality (TRM) was determined from the date of
transplantation to death related to transplantation.
Patients who died from other causes were censored
at time of death. Estimates for relapse incidence and
TRM were made using cumulative incidence esti-
mates. The following factors were included: age,
HLA-match, diagnosis, standard conditioning versus
RIC, good versus bad risk, total body irradiation
(TBI) versus non-TBI, graft source. Factors that
had value of P\ .05 were entered in a multivariable
Cox regression model (forward elimination) to deter-
mine independent predictors. The results were pre-
sented as hazard ratio (HR) together with the 95%confidence interval (CI) and P-values. Calculations
were performed in SPSS version 12.0 (SPSS, Chicago,
IL). The cumulative incidences were analyzed with the
Gray-test (according to National Health and Medical
Research Council, Clinical Trial Center, University
of Sydney, 2007, Prof. Val Gebski).
RESULTS
Engraftment
All but 2 patients experienced stable engraftment of
leukocytes and platelets. Two patients (1%) who expe-
rienced primary graft failure had been transplanted
from 10/10-matched donors, whereas none of the mis-
match-transplanted patients had primary graft failure.
The median time to leukocyte engraftment was 16
days in the matched as well as in the mismatched group
(range: 11–29 days, and 10-27 days, respectively)
(P 5 .9). The median time to platelet engraftment
(.20  109/L) was 23 days (range: 9-145 days) for
Table 2. Characteristics of HLA-Mismatches (mm)
Class I mm n 5 134
Class II mm n 5 54
1 mm class I/II n 5 91
2 mm class I/II n 5 44
3 mm class I/II n 5 15
4 mm class I/II n 5 8
Class I
A-mismatch n 5 17
Allele mismatch n 5 12
Antigen mismatch n 5 5
B-mismatch n 5 40
Allele mismatch n 5 31
Antigen mismatch n 5 9
C-mismatch n 5 116
Allele mismatch n 5 14
Antigen mismatch n 5 95
Allele and antigen mismatch n 5 7
KIR-ligand mismatch n 5 39
Overall class I
1 mismatch n 5 87
>2 mismatches n 5 47
Class II
DR-mismatch n 5 29
Allele mismatch n 5 24
Antigen mismatch n 5 5
DQ-mismatch n 5 35
Allele mismatch n 5 13
Antigen mismatch n 5 22
Overall class II
1 mismatch n 5 44
$2 mismatches n 5 10
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for the 9/10-mismatched group, and 18 days (range:
11-132 days) for the 6–8/10–mismatched group
(P 5 0.8).
GVHD
Overall, 42% of the study population did not expe-
rience any aGVHD. No aGVHDwas seen in 49% the
10/10-matched group, in 40%of the 9/10-mismatched
group, and in 35% of the 6–8/10-mismatched group.
The incidence of grade II-IV aGVHD was 33% of
the 10/10-matched group, 41% in the 9/10-mis-
matched-group, and 40% in the 6-8/10-mismatched-
group (P 5 .1). Severe grade III-IV aGVHD was seen
in 18% of the 10/10-matched group, in 15% of the 9/
10-mismatched-group, and in 23% of the 6-8/10-mis-
matched group. The overall rate of cGVHD was 42%
in the 10/10-matched group, 37% in the 9/10-mis-
matched group, and 46% in the 6-8/10-mismatched
group (P 5 .8). Severe extensive GVHD was seen in
17% of the 10/10-matched patients, and in 19% each
in the 9/10-mismatched and in the 6-8/10-mismatched
groups (P5 .8) (Table 3).
TRM
The cumulative incidence of TRM at 3 years for
the whole study group was 30% (95% CI: 25-35).
Causes of death were infectious complications (45%),
toxicity (25%), GVHD (25%), posttransplant lym-
phoma (3%), graft failure (1%), and secondary cancer(1%). TRM in the 10/10-matched group was 27%; in
the 9/10-mismatched group 31%, and in the 6-8/10-
mismatched group 33% (P5 .2) (Figure 1). Significant
factors for higher TRM in the univariate analysis were
age, either as continuous variables or, in case cutoffs
were used, as variables. Patients with good-risk disease
had a significantly lower treatment-related mortality
compared to patients with bad-risk disease (24% ver-
sus 39%) (P 5 .02) (Table 4), whereas HLA-matched
versus HLA-mismatched did not influence TRM
(29% versus 34%) (P 5 .2). Even patients with bad
risk disease, the treatment-related mortality did not
differ between the 10/10-matched, the 9/10-mis-
matched, and the 6-8/10-mismatched group (34%
versus 38% versus 51%) (P 5 .4). In a multivariate
analysis, only age as a continuous variable (HR 1.023)
(P\ .001) significantly influenced TRM (Table 5).
Relapse
Thecumulative incidenceof relapse at5 years for the
entire study population was 27% (95% CI: 21-33%).
There was no difference in the cumulative incidence of
relapse between the 10/10-matched, the 9/10-mis-
matched, and the 6-8/10-mismatched group (28%
versus 27% versus 26%) (P5 .9) (Figure 2). There was
alsono significant difference in the cumulative incidence
of relapse if mismatching was restricted only to patients
with bad risk (49%versus 53%versus 47%) (P5 0.3). In
an univariate analysis, significant factors for higher
relapse incidence (cumulative incidence at 5 years)
were lymphoid malignancies: NHL, MM, CLL, HD
(70%) versus acute lymphoblastic leukemia (ALL), acute
myelogenous leukemia (AML), MDS (36%) versus
CML,myelofibrosis (24%) (P5 .01). Other risk factors
for higher incidence of relapse within the univariate
analysis were bad-risk disease in comparison to good-
risk disease (51% versus 18%) (P\ .001), and RIC ver-
sus standard intensity conditioning (62% versus 26%)
(P5 .001). In the multivariate analysis, the only signif-
icant factors for a higher incidence of relapse at 5 years
were bad-risk diseases (HR 5 2.966) (P\ .001).
DFS
After a median follow-up of 35 months (range:
3-120 months), the 5-year estimated DFS rate for
the entire study group was 42%. It did not differ
among the 10/10-matched, the 9/10-mismatched,
and the 6-8/10-mismatched groups (45% versus 42%
versus 39%) (P 5 .5) (Figures 3 and 4). In the univar-
iate analysis, significant factors for an improved DFS
were younger age (P 5 .001), nonmalignant disease
(P 5 .002), good-risk disease (P\ .001), and standard
conditioning (P 5 .006). In the multivariate analysis,
only age (HR5 1.013) (P5 .004) and bad-risk disease
(HR 5 1975) (P\ .001) remained independent risk
factors for DFS.
Table 3. Results
All Patients n 5 268
Matched 10/10
(n 5 110)
Mismatched 9/10
(n 5 91)
Mismatched 6-8/10
(n 5 67) P-Value
Primary graft-failure n 5 2 (1%) n 5 2 n 5 0 n 5 0 .2
Median leukocyte
engraftment (>1.0  109/
L)
16 days (range, 10-38) 16 days (range, 10-38) 16 days (range, 11-29) 16 days (range, 10-27) .9
Median platelet
engraftment (>20  109/
L) (median)
21 days (range, 9-145) 23 days (range, 9-145) 21 days (range, 11-90) 18 days (range, 11-132) .8
Acute graft-versus-host
disease (aGVHD)
.1
Grade 0 n 5 112 (42%) n 5 53 (49%) n 5 36 (40%) n 5 23 (35%)
Grade 1 n 5 54 (20%) n 5 20 (19%) n 5 18 (20%) n 516 (25%)
Grade 2 n 5 50 (18%) n 5 16 (15%) n 5 23 (26%) n 5 11 (17%)
Grade 3 n 5 31 (12%) n 5 16 (15%) n 5 6 (7%) n 5 8 (12%)
Grade 4 n 5 17 (6%) n 5 3 (3%) n 5 7 (8%) n 5 7 (11%)
Chronic graft-versus-host
disease (cGVHD)
.8
None n 5 123 (58%) n 5 53 (58%) n 5 37 (55%) n 5 33 (63%)
Limited n 5 50 (24%) n 5 23 (25%) n 5 18 (27%) n 5 9 (17%)
Extensive n 5 40 (19%) n 5 16 (17%) n 5 13 (19%) n 5 10 (19%)
Cumulative incidence
of TRM (3 years)
30% (95% CI: 25-35%) 27% (95% CI: 19-35%) 31% (95% CI: 21-41%) 33% (95% CI: 21-45%) .2
Cumulative incidence
of relapse (5 years)
27% (95% CI: 21-33%) 28% (95% CI: 18-38%) 27% (95% CI: 17-37%) 26% (95% CI: 14-38%) .9
Estimated disease-free
survival (DFS) (5 years)
42% (95% CI: 36-48) 45% (95% CI: 35-55%) 42% (95% CI: 31-53%) 39% (95% CI: 26-52%) .5
Estimated overall
survival (OS) (5 years)
51% (95% CI: 45-57) 53% (95% CI: 43-63%) 55% (95% CI: 44-66%) 41% (95% CI: 28-54%) .3
Estimated OS
For good-risk patients 67% (95% CI: 58-76) 67% (95% CI: 53-81%) 72% (95% CI: 58-86%) 62% (95% CI: 40-84%) .9
For bad-risk patients 40% (95% CI: 32-48) 45% (95% CI: 29-61%) 43% (95% CI: 29-57%) 26% (95% CI: 10-42%) .2
Estimated DFS
For good-risk patients 61% (95% CI: 51-71) 62% (95% CI: 47-77%) 64% (95% CI: 49-79%) 59% (95% CI: 37-81%) .9
For bad-risk patients 29% (95% CI: 21-37) 33% (95% CI: 19-47%) 28% (95% CI: 14-42%) 26% (95% CI: 12-40%) .2
Estimated incidence
of relapse
For good-risk patients 18% (95% CI: 9-27) 20% (95% CI: 6-34%) 16% (95% CI: 2-30%) 18% (95% CI: 0-38%) .7
For bad-risk patients 51% (95% CI: 40-62) 49% (95% CI: 31-67%) 53% (95% CI: 37-73%) 47% (95% CI: 27-67%) .3
Estimated incidence
of TRM
For good-risk patients 24% (95% CI: 16-32) 23% (95% CI: 9-39%) 24% (95% CI: 10-38%) 22% (95% CI: 6-38%) .9
For bad-risk patients 39% (95% CI: 31-47) 34% (95% CI: 21-47) 38% (95% CI: 24-52%) 51% (95% CI: 31-71%) .4
TRM indicates treatment-related mortality.
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The estimated 5-year OS rate was 41% (95% CI:
45%-57%). There was no statistical difference among
the 10/10-matched, the 9/10-mismatched, and the 6-
8/10-mismatched groups (53% versus 55% versus
41%) (P5 .3) (Figures 3 and 4). In the univariate anal-
ysis, significant factors for an improved OS were youn-
ger age (P\ .001), nonmalignant disease (P\ .001),
good-risk disease (P \ .001), and standard-intensity
conditioning (P 5 .03). In a multivariate analysis, age
as continuous variable (HR 5 1.017) (P 5 .001), and
bad-risk disease (HR5 1.920) (P5 .001) remained in-
dependent significant factors for OS.Influence of HLA-Mismatch
We analyzed locus or class mismatches and mis-
match combinations with respect to treatment-related
mortality, relapse, and survival. For the majority of
single mismatches the number of patients was toosmall to perform valid analysis. The only significant
factor was a combined B- and A-allele-mismatches
resulted in a significantly worse OS in comparison to
10/10-matched patients (35% versus 53%) (P 5 .04).
All other singlemismatches ormismatch combinations
did not influence treatment-related mortality, relapse,
DFS, and OS.DISCUSSION
This large single-center experience using ATG as
part of the conditioning regimen for unrelated SCT
showed that up to 4 mismatches either on the allele-
or antigen-level can be tolerated without an obvious
increased risk of aGVHD and cGVHD or TRM, re-
sulting in a comparable OS and DFS as being achieved
for patients with high-resolution completely matched-
HLA-A, -B, -C, -DRB1, and -DQB1-matched hema-
topoietic stem cell donors. This is 1 of the first reports
suggesting that by modifying the GVHD-prophylaxis,
Figure 1. Cumulative incidence of TRM according to HLA-matching.
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tolerated without worsening survival rates. Similar re-
sults have been reported previously, but the respective
analyses were based only on serologic class I-typing
(without HLA–C) and high-resolution typing only
for class II. These results are of interest because there
is general agreement that increasing genetic disparity
on HLA-molecules is associated with a higher risk of
aGVHD, a higher TRM, and a lower survival in unre-
lated SCT [7,8,10-12,14-18,20-22]. However, which
antigen- or allele-mismatches are of most clinical rele-
vance is still a matter of debate. A recent analysis of theTable 4. Univariate Analysis of Overall Survival (OS), Disease-Free
Years (269 Patients)
OS
at 5 Years
% (Range)
P-
value
DFS at 5 Y
% (Rang
Age
0-20 years 75 (64-86) 63% (51-7
21-50 years 42 (33-51) <.001 36% (27-4
51-68 years 42 (30-54) 31% (18-4
Diagnosis
ALL, AML, 44 (35-53) 42 (33-5
MDS 70 (58-82) 58 (44-7
CML, PMF 35 (21-49) <.001 16 (4-28
NHL, MM, CLL, HD NMD 86 (71-100) 70 (50-9
Risk factor
Good risk 67 (58-76) <.001 61 (51-7
Bad risk 40 (32-48) 29 (21-3
Conditioning
Standard intensity 57 (49-65) 51 (43-5
Reduced intensity 38 (27-49) .03 23 (12-3
Age (contin.) HR 1.020
(95% CI: 1.010-1.030)
<.001 HR 1.017
(95% CI: 1.00
HLA-mismatch
10/10 match 53 (43-63) .2 45 (33-5
Mismatch 49 (41-57) 41 (33-4
ALL indicates acute lymphoblastic leukemia; AML, acute myelogenous leuke
leukemia; CMV, cytomegalovirus; MM, multiple myeloma; HD, Hodgkin dise
PMF, primary myelofibrosis; NMD, Non-malignant diseases.NMDP, which included 3857 transplant procedures,
suggested that high-resolution DNA-matching for
HLA-A, -B, -C, or -DRB1 (8/8) was confirmed as min-
imum matching-level associated with highest survival.
A single mismatch detected either by low- or high-
resolution DNA testing at HLA-A, -B, -C, or -DRB1
(7/8) was associated with a higher mortality, and a
1-year survival rate of 43% compared to 55% for the
8/8-matched pairs. In this analysis, each mismatch
was associated with a reduced survival, but mismatches
at HLA-B or -C may be better tolerated than those on
HLA-A or -DRB1. Furthermore, there was no differ-
ence whether the mismatch was seen at the allele-level
or at the antigen-level, except forHLA-C, in which the
allele-mismatch was better tolerated [7]. This analysis
was restricted only to standard-myeloablative condi-
tioning for patients with AML, ALL, CML, and
MDS, and the stem cell source was primarily bone
marrow. In contrast to our study, in which all patients
received ATG, in the NMDP study, only 22% of the
patients received some form of T cell-depleted grafts,
but no detailed information about in vivo or in vitro T
cell depletion was given. In another study from the
Fred Hutchinson Cancer Center in Seattle, HLA-
DRB1 allele-mismatch was associated with a high
rate of aGVHD, and of mortality [11]. Later on, the
same group reported on 471 CML patients who
underwent allogeneic SCT from an unrelated donor,
and they reported that single-antigen, but not allele-
class I mismatches, were associated with an increased
risk of graft failure, whereas the survival at 5 years
did not differ significantly among single class I allele-Survival (DFS), Relapse, and Treatment-Related Mortality at 5
ears
e)
P-
Value
Relapse
at 5 Years
% (Range)
P-
Value
Treatment-Related
Mortality
at 3 Years
% (Range) P-Value
5) 14 (6-22)
5) .001 36 (27-45) .003
4) 43 (30-56)
1) 36 (26-46)
2) 24 (10-38)
) .002 70 (50-90) .01
0) 11 (0-25)
1) <.001 18 (10-26) <.001 24 (16-32) .02
7) 51 (40-62) 39 (31-47)
9) 26 (18-34)
4) .006 62 (45-79) .001
8-1.026)
<.001 HR 1.023
(95% CI: 1.010-1.036)
<.001
7) .2 36 (24-48) .7 29 (20-38) .2
9) 37 (27-47) 34 (26-42)
mia; CLL, chronic lymphoblastic leukemia; CML, chronic myelogenous
ase; NHL, non-Hodgkin lymphoma; MDS, myelodysplastic syndromes;
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Table 5. Multivariate Analysis of Treatment-Related Mortality, Relapse, Disease-Free Survival (DFS), and Overall Survival (OS) at
5 Years (269 Patients)
Treatment-
Related
Mortality
at 3 Years
HR (95% CI) P-Value
Relapse
at 5 Years
HR (95% CI) P-Value
DFS
at 5 Years
HR (95% CI) P-Value
OS at 5 Years
HR (95% CI) P-Value
Age (contin.) 1.023 (1.010-1.036) <.001 1.013
(1.004-1.022)
.003 1.017
(1.007-1.027)
.001
Bad-risk disease 2.966
(1.682-5.229)
<.001 1.975
(1.004-1.022)
<.001 1.920
(1.283-2.859)
.001
460 Biol Blood Marrow Transplant 15:454-462, 2009N. Kro¨ger et al.mismatched pairs, single class I antigen-mismatched
pairs, and matched patients [10]. In 2004, the same
group extended their analysis to 948 patients and re-
ported single allele- or antigen-mismatch was associ-
ated with a higher mortality in CML in chronic
phase within 2 years of diagnosis, but not in patients
withmore advanced disease. In detail, a single disparity
at HLA-C was associated with a lower survival than it
was with HLA-DQB1-mismatch in combination with
othermismatches. As in the recently publishedNMDP
study, the Seattle group also found that a single allele
and a single antigen mismatch had similar mortality
results. In contrast to this group, the NMDP study
has also clearly shown a lower survival for mismatched
transplantation in patients with advanced disease
phases. Another large study from the JapaneseMarrow
Donor Program ( JMDP) reported on 1298 SCTs.
It found that each mismatch on HLA-A, -B, -C, or
-DRB1 and -DQB1 was associated with a higher risk
of grade III-IV aGVHD, but that only HLA-A and -B
mismatches were associated with a higher mortality,
and with cGVHD [8]. Besides the aforementioned
NMDP study from 2007, the NMDP published 2
earlier studies examining the HLA-matching in adult
unrelated donor hematopoietic SCT. In 1 analysis,Figure 2. Cumulative incidence of relapse according to HLA-matching.831 patients with CML in chronic or accelerated phase
were investigated, and HLA-DRB1 allele mismatching
was associated with a lower relapse-free survival (RFS)
aswell aswith lowerOS [17]. Later on, theNMDPpub-
lished another study analyzing 1874 transplantations,
and reported that low-resolution mismatches at HLA-
A, -B, -C, and -DRB1 were associated with a worse
survival, whereas mismatches detected with high-
resolution typing were not associated with a lower sur-
vival [19]. Other studies including less than 200 patients
confirmed the negative impact ofHLA-mismatching ondays after transplantation
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Figure 3. DFS (A) and OS (B) of 10/10-allele-matched, 9/10-allele-
mismatched, and 6-8/10-allele-mismatched unrelated donor SCT.
Figure 4. DFS (A) and OS (B) in good-risk or bad-risk disease accord-
ing to HLA-matching.
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donors [20-22].
Therefore, almost all studies published so far con-
firmed the negative influence of HLA-mismatch on
outcome after allogeneic SCT from unrelated donors.
Onemight ask why our study did not show similar dec-
rements in survival depending on HLA-mismatch.
Similar to other studies, the influence of unrelated
SCT in a multivariate analysis was mainly influenced
by age and disease status, indicating that no selection
bias of the patients could be the reason. In contrast to
all other reported studies, all our patients received
ATG as part of the conditioning regimen to prevent
aGVHD. A positive effect of ATG to prevent GVHD
has been reported in several studies [23-28]. In some
of those studies, small portions of mismatched-unre-
lated donors were included with a similar outcome to
those with completely HLA-matched donor [27,28].
Therefore, the main reason for the encouraging results
in mismatched-unrelated SCT is probably because of
the similar incidence of aGVHD and cGVHD in the
10/10-matched and the mismatched cohort.
Further more, it is of note that no graft failure
was observed after HLA-mismatched transplantation.Both the incidence of aGVHD and cGVHD, as well
as graft failure, influenced mostly the negative out-
come of mismatched transplantation in the aforemen-
tioned studies. In contrast to other T cell-depleting
methods [17], there was no obvious increase of relapse
using ATG as GVHD prophylaxis, but because no
non-ATG control group existed, no valid information
can be given for ATG and an increased risk of relapse.
A Chinese group that transplanted mainly leukemia pa-
tients with multiple HLA-mismatched related donors
without in vitro T cell depletion reported a similar
observation. Besides the combined bone marrow and
peripheral blood SCT, the group also used high-dose
ATG to prevent aGVHD, and it found no influence
of the occurrence of GVHD by the HLA-disparity
[29]. We conclude that the current study provides evi-
dence that the negative impact of HLA-disparity in
allogeneic SCT from unrelated donor can be overcome
by using ATG to prevent GVHD and primary graft
failure. This treatment strategy offers new transplant
possibilities for patients lacking an HLA-identical
sibling or a fully matched unrelated donor.ACKNOWLEDGMENTS
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